Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Business Team Staffer to Head SYN X s Development Efforts

NEW YORK, March 12 – Aaron Davidson, previously a member of Eli Lilly’s corporate development team, has been named vice president of business development at SYN X Pharma, the company said Monday.

SYN X, a Toronto-based proteomics company is looking to launch deals for therapeutics and diagnostics stemming from the company’s initiatives.

During his nine-year tenure with Eli Lilly, Davidson completed a number of multi-million dollar in- licensing, out-partnering, and distribution deals in the areas of epilepsy, Parkinson's disease, and oncology. 

At SYN X Davidson will be responsible for developing and accelerating strategic alliances for the company’s Proteomics Discovery Platform, which can be used to identify protein targets for the development of new drugs and antibody-based diagnostics. 

The company is currently developing diagnostics for diabetes, cardiovascular and central nervous system diseases.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.